{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:31:20Z","timestamp":1792791080987,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010463","name":"Institut Curie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010463","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institut de Recherche Servier","id":[{"id":"https:\/\/ror.org\/01zej3n42","id-type":"ROR","asserted-by":"crossref"}]},{"name":"PRESTIGE postdoctoral mobility grant award coordinated by Campus France and co-financed by Marie Sk\u0142odowska-Curie actions","award":["PCOFUND-GA-2013-609102"],"award-info":[{"award-number":["PCOFUND-GA-2013-609102"]}]},{"name":"\u00c9quipe Labellis\u00e9e LIGUE Contre Le Cancer"},{"name":"ANR","award":["ANR-10-EQPX-03"],"award-info":[{"award-number":["ANR-10-EQPX-03"]}]},{"name":"ITMO-Cancer Aviesan"},{"name":"SiRIC-Curie program","award":["INCa-DGOS-465"],"award-info":[{"award-number":["INCa-DGOS-465"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aberrant activation of the Wnt signaling pathway in triple-negative breast cancer (TNBC) is linked to treatment resistance and recurrence, yet its role in tumoral heterogeneity remains unclear. We developed Wnt reporter cell lines from two mesenchymal TNBC models (MDA-MB-231 and MDA-MB-436) using a Tcf\/Lef-eGFP vector and observed intra- and inter-cellular variation in Wnt activity. Paired Wnt-positive and Wnt-negative TNBC cell lines were established and profiled by RNA-Seq.\u00a0Integrative analyses revealed that Wnt-positive cells consistently upregulate genes involved in epithelial-to-mesenchymal transition, inflammation (e.g., IL6\/JAK\/STAT3, TNF\u03b1 via NF-\u03baB), and extracellular matrix remodeling. A 55-gene Wnt signature common to both low and standard serum conditions captured these features. Wnt-related gene sets were also enriched in the mesenchymal-like immune-altered (MLIA) subtype of 699 primary TNBC tumors. These findings highlight the role of basal Wnt activity in driving pro-tumorigenic transcriptional programs in TNBC and provide new insight into its contribution to subtype-specific disease features.<\/jats:p>","DOI":"10.1038\/s41598-026-43678-3","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:24:01Z","timestamp":1775136241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Wnt signaling promotes inflammation and EMT-associated gene expression in mesenchymal TNBC"],"prefix":"10.1038","volume":"16","author":[{"given":"Ram\u00f3n","family":"Garc\u00eda-Areas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Lasla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Raynal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Servant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"J\u00e9z\u00e9quel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"43678_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J.-J., Bian, X.-W. & Yu, S.-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61 (2020).","journal-title":"Breast Cancer Res."},{"issue":"Suppl 6","key":"43678_CR2","doi-asserted-by":"publisher","first-page":"vi19","DOI":"10.1093\/annonc\/mds190","volume":"23","author":"F Penault-Llorca","year":"2012","unstructured":"Penault-Llorca, F. & Viale, G. Pathological and molecular diagnosis of triple-negative breast cancer: A clinical perspective. Ann. Oncol. 23(Suppl 6), vi19-22 (2012).","journal-title":"Ann. Oncol."},{"key":"43678_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938\u20131948 (2010).","journal-title":"N. Engl. J. Med."},{"key":"43678_CR4","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey, L. A. et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329\u20132334 (2007).","journal-title":"Clin. Cancer Res."},{"key":"43678_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2741\/4558","volume":"22","author":"N Wright","year":"2017","unstructured":"Wright, N., Rida, P. C. G. & Aneja, R. Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer. Front. Biosci. 22, 1549\u20131580 (2017).","journal-title":"Front. Biosci."},{"key":"43678_CR6","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann, B. D. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121, 2750\u20132767 (2011).","journal-title":"J. Clin. Invest."},{"key":"43678_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of triple-negative breast cancer molecular subtypes: Implications for neoadjuvant chemotherapy selection. PLoS One 11, e0157368 (2016).","journal-title":"PLoS One"},{"key":"43678_CR8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2014","unstructured":"Burstein, M. D. et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 21, 1688\u20131698 (2014).","journal-title":"Clin. Cancer Res."},{"key":"43678_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12282-024-01597-z","volume":"31","author":"P J\u00e9z\u00e9quel","year":"2024","unstructured":"J\u00e9z\u00e9quel, P. et al. Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype. Breast Cancer 31, 825\u2013840 (2024).","journal-title":"Breast Cancer"},{"issue":"Suppl 6","key":"43678_CR10","doi-asserted-by":"publisher","first-page":"vi46","DOI":"10.1093\/annonc\/mds195","volume":"23","author":"F Andr\u00e9","year":"2012","unstructured":"Andr\u00e9, F. & Zielinski, C. C. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann. Oncol. 23(Suppl 6), vi46\u201351 (2012).","journal-title":"Ann. Oncol."},{"key":"43678_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082204","author":"MA Subhan","year":"2023","unstructured":"Subhan, M. A. et al. Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type. Cancers (Basel) 15, 2204 (2023).","journal-title":"Cancers (Basel)"},{"key":"43678_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121270","volume":"14","author":"M Yordanova","year":"2021","unstructured":"Yordanova, M., Hubert, A. & Hassan, S. Expanding the use of PARP inhibitors as monotherapy and in combination in triple-negative breast cancer. Pharmaceuticals (Basel) 14, 1270 (2021).","journal-title":"Pharmaceuticals (Basel)"},{"key":"43678_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00071-6","volume":"3","author":"R Yang","year":"2022","unstructured":"Yang, R. et al. Therapeutic progress and challenges for triple negative breast cancer: Targeted therapy and immunotherapy. Mol. Biomed. 3, 8 (2022).","journal-title":"Mol. Biomed."},{"key":"43678_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10555-021-09972-4","volume":"40","author":"AL Heeke","year":"2021","unstructured":"Heeke, A. L. & Tan, A. R. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 40, 537\u2013547 (2021).","journal-title":"Cancer Metastasis Rev."},{"key":"43678_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes, J. et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N. Engl. J. Med. 387, 217\u2013226 (2022).","journal-title":"N. Engl. J. Med."},{"key":"43678_CR16","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N Engl. J. Med. 382, 810\u2013821 (2020).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"43678_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","volume":"8","author":"P Zagami","year":"2022","unstructured":"Zagami, P. & Carey, L. A. Triple negative breast cancer: Pitfalls and progress. npj Breast Cancer 8, 95.https:\/\/doi.org\/10.1038\/s41523-022-00468-0 (2022).","journal-title":"npj Breast Cancer"},{"key":"43678_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/287795a0","volume":"287","author":"C N\u00fcsslein-Volhard","year":"1980","unstructured":"N\u00fcsslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795\u2013801 (1980).","journal-title":"Nature"},{"key":"43678_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0092-8674(82)90409-3","volume":"31","author":"R Nusse","year":"1982","unstructured":"Nusse, R. & Varmus, H. E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99\u2013109 (1982).","journal-title":"Cell"},{"key":"43678_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(87)90038-9","volume":"50","author":"F Rijsewijk","year":"1987","unstructured":"Rijsewijk, F. et al. The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell 50, 649\u2013657 (1987).","journal-title":"Cell"},{"key":"43678_CR21","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0092-8674(91)90633-A","volume":"64","author":"R Nusse","year":"1991","unstructured":"Nusse, R. et al. A new nomenclature for int-1 and related genes: The Wnt gene family. Cell 64, 231 (1991).","journal-title":"Cell"},{"key":"43678_CR22","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse, R. & Clevers, H. Wnt\/\u03b2-Catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985\u2013999 (2017).","journal-title":"Cell"},{"key":"43678_CR23","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1038\/oncsis.2017.14","volume":"6","author":"SG Pohl","year":"2017","unstructured":"Pohl, S. G. et al. Wnt signaling in triple-negative breast cancer. Oncogenesis 6, e310 (2017).","journal-title":"Oncogenesis"},{"key":"43678_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/stem.3301","volume":"39","author":"S Ehmsen","year":"2021","unstructured":"Ehmsen, S. & Ditzel, H. J. Signaling pathways essential for triple-negative breast cancer stem-like cells. Stem Cells. 39, 133\u2013143 (2021).","journal-title":"Stem Cells"},{"issue":"1","key":"43678_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12935-021-02107-3","volume":"21","author":"P Merikhian","year":"2021","unstructured":"Merikhian, P., Eisavand, M. R. & Farahmand, L. Triple-negative breast cancer: Understanding Wnt signaling in drug resistance. Cancer Cell Int. 21, 419\u00a0(2021).","journal-title":"Cancer Cell Int."},{"key":"43678_CR26","doi-asserted-by":"crossref","unstructured":"Maire, V., Mahmood, F., Rigaill, G. et al. LRP8 is overexpressed in estrogen\u2011negative breast cancers and a potential target for these tumors. Cancer Med 8, 325\u2013336 (2019).","DOI":"10.1002\/cam4.1923"},{"key":"43678_CR27","doi-asserted-by":"publisher","first-page":"22586","DOI":"10.18632\/oncotarget.25187","volume":"9","author":"S Maubant","year":"2018","unstructured":"Maubant, S. et al. LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers. Oncotarget 9, 22586\u201322604 (2018).","journal-title":"Oncotarget"},{"key":"43678_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122333","volume":"10","author":"S Maubant","year":"2015","unstructured":"Maubant, S. et al. Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One 10, e0122333 (2015).","journal-title":"PLoS One"},{"key":"43678_CR29","doi-asserted-by":"crossref","unstructured":"Suresh, S. et al. PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer. Cancers (Basel) 14, 306 (2022).","DOI":"10.3390\/cancers14020306"},{"key":"43678_CR30","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","volume":"36","author":"T Zhan","year":"2017","unstructured":"Zhan, T., Rindtorff, N. & Boutros, M. Wnt signaling in cancer. Oncogene 36, 1461\u20131473 (2017).","journal-title":"Oncogene"},{"key":"43678_CR31","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1111\/cas.13771","volume":"109","author":"P Yin","year":"2018","unstructured":"Yin, P. et al. Wnt signaling in human and mouse breast cancer: Focusing on Wnt ligands, receptors and antagonists. Cancer Sci. 109, 3368\u20133375 (2018).","journal-title":"Cancer Sci."},{"key":"43678_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8070070","author":"D Hrckulak","year":"2016","unstructured":"Hrckulak, D., Kolar, M., Strnad, H. & Korinek, V. TCF\/LEF transcription factors: an update from the internet resources. Cancers (Basel) 8, 70 (2016).","journal-title":"Cancers"},{"key":"43678_CR33","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S0092-8674(00)81925-X","volume":"88","author":"M van de Wetering","year":"1997","unstructured":"van de Wetering, M. et al. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88, 789\u2013799 (1997).","journal-title":"Cell"},{"key":"43678_CR34","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1126\/science.275.5307.1784","volume":"275","author":"V Korinek","year":"1997","unstructured":"Korinek, V. et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-\/- colon carcinoma. Science 275, 1784\u20131787 (1997).","journal-title":"Science"},{"key":"43678_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009370","volume":"5","author":"C Fuerer","year":"2010","unstructured":"Fuerer, C. & Nusse, R. Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 5, e9370 (2010).","journal-title":"PLoS One"},{"key":"43678_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-cellbio-120319-023657","volume":"37","author":"LV Albrecht","year":"2021","unstructured":"Albrecht, L. V., Tejeda-Mu\u00f1oz, N. & De Robertis, E. M. Cell Biology of Canonical Wnt Signaling. Annu. Rev. Cell. Dev. Biol. 37, 369\u2013389 (2021).","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"key":"43678_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aan3000","author":"A Aloysius","year":"2018","unstructured":"Aloysius, A., DasGupta, R. & Dhawan, J. The transcription factor Lef1 switches partners from \u03b2-catenin to Smad3 during muscle stem cell quiescence. Sci. Signal\u00a011, eaan3000 (2018).","journal-title":"Sci. Signal."},{"key":"43678_CR38","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/1878-0261.12167","volume":"12","author":"A Sulaiman","year":"2018","unstructured":"Sulaiman, A. et al. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. Mol. Oncol. 12, 423\u2013440 (2018).","journal-title":"Mol. Oncol."},{"key":"43678_CR39","doi-asserted-by":"crossref","unstructured":"Abreu de Oliveira, W. A. et al. Wnt\/\u03b2-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Front. Oncol. 11, 705384 (2021).","DOI":"10.3389\/fonc.2021.705384"},{"key":"43678_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3390\/ph17070949","volume":"17","author":"A de Pellegars-Malhortie","year":"2024","unstructured":"de Pellegars-Malhortie, A., Lasorsa, P., Mazard, L., Granier, T., Pr\u00e9vostel, C. & F. & Why is Wnt\/\u03b2-catenin not yet targeted in routine cancer care? Pharmaceuticals (Basel). 17, 949 (2024).","journal-title":"Pharmaceuticals (Basel)"},{"key":"43678_CR41","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1038\/cddis.2015.171","volume":"6","author":"E Lee","year":"2015","unstructured":"Lee, E. et al. Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition. Cell. Death Dis. 6, e1805 (2015).","journal-title":"Cell. Death Dis."},{"key":"43678_CR42","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/mc.23234","volume":"59","author":"NN Alraouji","year":"2020","unstructured":"Alraouji, N. N. et al. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol. Carcinog. 59, 1041\u20131051 (2020).","journal-title":"Mol. Carcinog."},{"key":"43678_CR43","doi-asserted-by":"publisher","first-page":"e2200750","DOI":"10.1002\/advs.202200750","volume":"9","author":"S Zheng","year":"2022","unstructured":"Zheng, S. et al. Aberrant Cholesterol Metabolism and Wnt\/\u03b2-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth. Adv. Sci. 9, e2200750 (2022).","journal-title":"Adv. Sci."},{"key":"43678_CR44","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41419-018-0876-3","volume":"9","author":"N Wang","year":"2018","unstructured":"Wang, N. et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-\u03baB\/SOX4 signaling. Cell. Death Dis. 9, 880 (2018).","journal-title":"Cell. Death Dis."},{"key":"43678_CR45","doi-asserted-by":"publisher","first-page":"689286","DOI":"10.3389\/fcell.2021.689286","volume":"9","author":"SL Ciummo","year":"2021","unstructured":"Ciummo, S. L. et al. The C-X-C motif chemokine ligand 1 sustains breast cancer stem cell self-renewal and promotes tumor progression and immune escape programs. Front. Cell. Dev. Biol. 9, 689286 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"43678_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107153","volume":"95","author":"G Nie","year":"2021","unstructured":"Nie, G. et al. Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin. Int. Immunopharmacol. 95, 107153 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"43678_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00040","volume":"9","author":"PA Ruffini","year":"2019","unstructured":"Ruffini, P. A. The CXCL8-CXCR1\/2 axis as a therapeutic target in breast cancer stem-like cells. Front. Oncol. 9, 40 (2019).","journal-title":"Front. Oncol."},{"key":"43678_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/BD-2010-0307","volume":"32","author":"KJ Chavez","year":"2010","unstructured":"Chavez, K. J., Garimella, S. V. & Lipkowitz, S. Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35\u201348 (2010).","journal-title":"Breast Dis."},{"key":"43678_CR49","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/ng.2007.39","volume":"40","author":"LH Saal","year":"2008","unstructured":"Saal, L. H. et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 40, 102\u2013107 (2008).","journal-title":"Nat. Genet."},{"key":"43678_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"43678_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","volume":"25","author":"S L\u00ea","year":"2008","unstructured":"L\u00ea, S., Josse, J. & Husson, F. FactoMineR: An R package for multivariate analysis. J. Stat. Softw. 25, 1\u201318 (2008).","journal-title":"J. Stat. Softw."},{"key":"43678_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).","journal-title":"Nat. Commun."},{"key":"43678_CR53","doi-asserted-by":"publisher","first-page":"D545","DOI":"10.1093\/nar\/gkaa970","volume":"49","author":"M Kanehisa","year":"2021","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. & Tanabe, M. KEGG: Integrating viruses and cellular organisms. Nucleic Acids Res. 49, D545\u2013D551 (2021).","journal-title":"Nucleic Acids Res."},{"key":"43678_CR54","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","volume":"36","author":"SX Ge","year":"2020","unstructured":"Ge, S. X., Jung, D. & Yao, R. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics 36, 2628\u20132629 (2020).","journal-title":"Bioinformatics"},{"key":"43678_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"43678_CR56","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jmb.2015.11.006","volume":"428","author":"M Kanehisa","year":"2016","unstructured":"Kanehisa, M., Sato, Y. & Morishima, K. BlastKOALA and GhostKOALA: KEGG tools for functional characterization of genome and metagenome sequences. J. Mol. Biol. 428, 726\u2013731 (2016).","journal-title":"J. Mol. Biol."},{"key":"43678_CR57","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"43678_CR58","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267\u2013273 (2003).","journal-title":"Nat. Genet."},{"key":"43678_CR59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular Signatures Database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"43678_CR60","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"43678_CR61","doi-asserted-by":"publisher","first-page":"W305","DOI":"10.1093\/nar\/gkp427","volume":"37","author":"J Chen","year":"2009","unstructured":"Chen, J., Bardes, E. E., Aronow, B. J. & Jegga, A. G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305\u2013W311 (2009).","journal-title":"Nucleic Acids Res."},{"key":"43678_CR62","doi-asserted-by":"crossref","unstructured":"Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R. & Pfister, H. UpSet: Visualization of intersecting sets. IEEE Trans. Vis. Comput. Graph. 20, 1983\u20131992 (2014).","DOI":"10.1109\/TVCG.2014.2346248"},{"key":"43678_CR63","doi-asserted-by":"crossref","unstructured":"Huppert, L.\u202fA., Gumusay, O. & Rugo, H.\u202fS. Emerging treatment strategies for metastatic triple\u2011negative breast cancer. Ther. Adv. Med. Oncol. 14, 17588359221086916 (2022).","DOI":"10.1177\/17588359221086916"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43678-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43678-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43678-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T09:02:24Z","timestamp":1779354144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43678-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43678"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43678-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.07.04.663027","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"24 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15798"}}